These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 25039675)

  • 21. Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes.
    Li R; Xu W; Luo S; Xu H; Tong G; Zeng L; Zhu D; Weng J
    Acta Diabetol; 2015 Dec; 52(6):1083-91. PubMed ID: 26249206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: a retrospective study from a specialist diabetes outpatient clinic.
    Carrington MJ; Chan YK; Stewart S; Sjouke B; Brazilek R; Cohen N
    Intern Med J; 2014 Apr; 44(4):345-53. PubMed ID: 24877253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
    Ann Intern Med; 2011 Jan; 154(2):I-40. PubMed ID: 21135289
    [No Abstract]   [Full Text] [Related]  

  • 24. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.
    Best JH; Rubin RR; Peyrot M; Li Y; Yan P; Malloy J; Garrison LP
    Diabetes Care; 2011 Feb; 34(2):314-9. PubMed ID: 21270189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.
    Samms RJ; Cheng CC; Fourcaudot M; Heikkinen S; Khattab A; Adams J; Cersosimo E; Triplitt C; Puckett C; Tsintzas K; Adams AC; Abdul-Ghani MA; DeFronzo RA; Norton L
    Am J Physiol Endocrinol Metab; 2022 Aug; 323(2):E123-E132. PubMed ID: 35723225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exenatide extended-release: a review of its use in type 2 diabetes mellitus.
    Scott LJ
    Drugs; 2012 Aug; 72(12):1679-707. PubMed ID: 22867046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy with pioglitazone/exenatide improves beta-cell function and produces superior glycaemic control compared with basal/bolus insulin in poorly controlled type 2 diabetes: A 3-year follow-up of the Qatar study.
    Abdul-Ghani M; Migahid O; Megahed A; DeFronzo RA; Al-Ozairi E; Jayyousi A
    Diabetes Obes Metab; 2020 Dec; 22(12):2287-2294. PubMed ID: 32729222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review.
    Ojo O
    Int J Environ Res Public Health; 2016 Sep; 13(10):. PubMed ID: 27669277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus.
    Vu A; Kosmiski LA; Beitelshees AL; Prigeon R; Sidhom MS; Bredbeck B; Predhomme J; Deininger KM; Aquilante CL
    Pharmacotherapy; 2016 Mar; 36(3):252-62. PubMed ID: 26822630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Substitution of insulin by exenatide in bad controlled type 2 diabetic patients: efficacy and predictive factors.
    Barthélémy M; Boullu Sanchis S; Moreau F; Reix N; Pinget M; Sigrist S; Jeandidier N
    Minerva Endocrinol; 2015 Sep; 40(3):155-61. PubMed ID: 25003223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.
    DeYoung MB; MacConell L; Sarin V; Trautmann M; Herbert P
    Diabetes Technol Ther; 2011 Nov; 13(11):1145-54. PubMed ID: 21751887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Association between SORCS1 rs1416406 and therapeutic effect of exenatide].
    Zhou LM; Xu W; Yan XM; Li MXY; Liang H; Weng JP
    Zhonghua Yi Xue Za Zhi; 2017 May; 97(18):1415-1419. PubMed ID: 28535629
    [No Abstract]   [Full Text] [Related]  

  • 33. Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy.
    Tobin GS; Cavaghan MK; Hoogwerf BJ; McGill JB
    Int J Clin Pract; 2012 Dec; 66(12):1147-57. PubMed ID: 23061886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes.
    Dorkhan M; Magnusson M; Frid A; Grubb A; Groop L; Jovinge S
    J Intern Med; 2006 Aug; 260(2):125-33. PubMed ID: 16882276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.
    DeFronzo RA; Triplitt C; Qu Y; Lewis MS; Maggs D; Glass LC
    Diabetes Care; 2010 May; 33(5):951-7. PubMed ID: 20107105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.
    Derosa G
    Drugs; 2010 Oct; 70(15):1945-61. PubMed ID: 20883052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome.
    Derosa G; Dangelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Cicero AF
    J Int Med Res; 2006; 34(5):545-55. PubMed ID: 17133785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Add on Exenatide Treatment is Beneficial in Poorly Controlled Obese Type 2 Diabetics under Intensive Insulin Regimens.
    Sönmez A; Dinç M; Taşlıpınar A; Aydoğdu A; Meriç C; Başaran Y; Haymana C; Demir O; Yılmaz İ; Azal Ö
    Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):256-261. PubMed ID: 28201828
    [No Abstract]   [Full Text] [Related]  

  • 39. Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity.
    Preumont V; Hermans MP; Brichard S; Buysschaert M
    Diabetes Metab; 2010 Sep; 36(4):293-8. PubMed ID: 20447851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.
    Weng J; Li Y; Xu W; Shi L; Zhang Q; Zhu D; Hu Y; Zhou Z; Yan X; Tian H; Ran X; Luo Z; Xian J; Yan L; Li F; Zeng L; Chen Y; Yang L; Yan S; Liu J; Li M; Fu Z; Cheng H
    Lancet; 2008 May; 371(9626):1753-60. PubMed ID: 18502299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.